SCHEMBL4049830

SCHEMBL4049830

CS(=O)(=O)OCc1ccc2ncccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
PDE10A Q9Y233 2/20 0.46
NPC1 O15118 2/20 0.45
POLB P06746 1/20 0.45
RAB9A P51151 1/20 0.45
HTT P42858 2/20 0.44
ALOX15 P16050 1/20 0.44
DAO P14920 1/20 0.44
CHKA P35790 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
CASP1 P29466 1/20 0.42
ATM Q13315 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HDAC3 O15379 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17444566 0.86 DAO (0.48) ALDH1A1PDE10ANPC1POLBRAB9A
SCHEMBL3136961 0.80 ALDH1A1 (0.53) ALDH1A1PDE10ANPC1POLBRAB9A
SCHEMBL553917 0.77 MET (0.41) PDE10AMET
SCHEMBL10198779 0.77 ALDH1A1 (0.50) ALDH1A1PDE10ANPC1POLBRAB9A
SCHEMBL27255825 0.77 ALOX15 (0.51) ALDH1A1NPC1POLBRAB9AHTT
SCHEMBL28272270 0.76 CYP1A2 (0.44) RAB9AKCNH2
SCHEMBL1520828 0.76 ALDH1A1 (0.53) ALDH1A1PDE10ANPC1POLBRAB9A
SCHEMBL7274371 0.76 NPC1 (0.47) ALDH1A1PDE10ANPC1POLBRAB9A
SCHEMBL28714141 0.76 HDAC3 (0.50) ALDH1A1NPC1POLBRAB9AHTT
SCHEMBL3365048 0.76 HDAC6 (0.49) ALDH1A1NPC1POLBRAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009111501-A1 DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-09-11 WO disclosed
US-20090226398-A1 ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GENELABS TECHNOLOGIES, INC. 2009-09-10 US disclosed
US-6362188-B1 ANTICANCER AGENTS SCHERING CORPORATION 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226398-A1 ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE MAVS, SARS1, HAVCR2 ALDH1A1 2203/4885PDE10A 1879/4885NPC1 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.